Department of Dermatology, Peking University People's Hospital, Beijing 100044, China; Department of Dermatology, Peking University International Hospital, Beijing 102206, China.
Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113474. doi: 10.1016/j.intimp.2024.113474. Epub 2024 Oct 29.
Long-term, real-world studies of the efficacy and metabolic parameters of ixekizumab in difficult-to-treat areas of psoriasis are lacking. A two-year retrospective study was conducted to evaluate the long-term efficacy, safety, drug survival and metabolic parameters of ixekizumab in the real world. A total of 258 patients were enrolled. At 52 weeks, PASI 75/90/100 was achieved in 92.0 %, 79.8 % and 54.6 % of patients, respectively. The efficacy was maintained at week 104 with PASI 75/90/100 of 92.6 %, 81.5 % and 48.1 %, respectively. At week 12, sPGA 0/1 was achieved in 71.0 % of scalp psoriasis, 60.0 % of palmoplantar psoriasis and 68.8 % of genital psoriasis. The probability of drug survival at 12 and 24 months was 67.1 % and 56.3 %, respectively. The most common adverse events included local injection reactions (31.8 %), allergies (11.6 %) and infections (6.1 %). No disease activation was observed in patients with latent tuberculosis or hepatitis B/C. No hyperlipidemia or hyperglycemia was observed. This study confirmed the long-term efficacy, high drug survival and favorable safety of ixekizumab in a real-world setting.
长期以来，缺乏依奇珠单抗在银屑病难治部位的疗效和代谢参数的真实世界研究。本回顾性研究旨在评估依奇珠单抗在真实世界中的长期疗效、安全性、药物生存和代谢参数。共纳入 258 例患者。第 52 周时，分别有 92.0%、79.8%和 54.6%的患者达到 PASI75/90/100 缓解；第 104 周时，分别有 92.6%、81.5%和 48.1%的患者达到 PASI75/90/100 缓解。第 12 周时，分别有 71.0%、60.0%和 68.8%的头皮银屑病、掌跖银屑病和生殖器银屑病患者的 sPGA 评分为 0/1。第 12 和 24 个月时的药物生存率分别为 67.1%和 56.3%。最常见的不良事件包括局部注射反应（31.8%）、过敏（11.6%）和感染（6.1%）。未观察到潜伏性结核或乙肝/丙肝患者的疾病激活。未观察到血脂异常或高血糖。本研究证实了依奇珠单抗在真实世界环境中的长期疗效、高药物生存率和良好的安全性。
